Why the study?
Fibrosis affects millions of people with cardiac disease, prompting the development of an in vivo therapeutic approach using CAR T cells to treat cardiac injury.
Does in vivo generation of CAR T cells using mRNA-targeted LNPs reduce fibrosis and restore cardiac function in a mouse model of heart failure?
Does in vivo generation of CAR T cells using mRNA-targeted LNPs reduce fibrosis and restore cardiac function in a mouse model of heart failure?
Answers are grounded in this paper and cite their sources.
In vivo generation of transient antifibrotic CAR T cells using mRNA-targeted LNPs successfully reduces fibrosis and restores cardiac function in a mouse model of heart failure.
Fibrosis affects millions of people with cardiac disease. We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA (mRNA) in T cell–targeted lipid nanoparticles (LNPs). The efficacy of these in vivo–reprogrammed CAR T cells was evaluated by injecting CD5-targeted LNPs into a mouse model of heart failure. Efficient delivery of modified mRNA encoding the CAR to T lymphocytes was observed, which produced transient, effective CAR T cells in vivo. Antifibrotic CAR T cells exhibited trogocytosis and retained the target antigen as they accumulated in the spleen. Treatment with modified mRNA-targeted LNPs reduced fibrosis and restored cardiac function after injury. In vivo generation of CAR T cells may hold promise as a therapeutic platform to treat various diseases.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: